托珠单抗治疗常规免疫调节和抗 TNF-α 治疗失败的非感染性葡萄膜炎的疗效和安全性。
Efficacy and Safety of Tocilizumab in the Management of Non-Infectious Uveitis Failed with Conventional Immunomodulatory and Anti-TNFα Therapies.
机构信息
Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.
出版信息
Ocul Immunol Inflamm. 2024 Aug;32(6):891-897. doi: 10.1080/09273948.2022.2126374. Epub 2022 Dec 21.
PURPOSE
To determine the outcomes of intravenous (IV) tocilizumab (TCZ) in patients with non-infectious uveitis who failed with conventional immunomodulatory and anti-TNFα therapies.
METHODS
Records of seven patients with non-infectious uveitis treated with monthly IV TCZ (4-10 mg/kg) or biweekly IV TCZ (8 mg/kg) were reviewed. Outcome measures were changes in visual acuity, anterior chamber cell and flare grade, vitreous haze, central subfield thickness (CST), and fluorescein angiography (FA) score.
RESULTS
Ten eyes of seven patients received TCZ therapy. Median age of patients was 14 (range, 7-24) years. Median duration of TCZ therapy was 15 (range, 5-32) months. Mean CST reduced from 373 ± 101.0 μm to 298.2 ± 40.3 μm. Mean FA score reduced from 12.5 ± 4.3 to 3.6 ± 2.6. One patient developed elevated liver transaminases.
CONCLUSION
IV TCZ is a potentially effective and safe therapeutic option for the management of refractory non-infectious uveitis.
目的
评估在常规免疫调节和抗 TNF-α 治疗失败的非感染性葡萄膜炎患者中，静脉注射（IV）托珠单抗（TCZ）的疗效。
方法
回顾性分析了 7 例接受每月 IV TCZ（4-10mg/kg）或每两周 IV TCZ（8mg/kg）治疗的非感染性葡萄膜炎患者的记录。观察指标包括视力变化、前房细胞和炎症反应分级、玻璃体混浊、中央视网膜厚度（CST）和荧光素血管造影（FA）评分。
结果
7 例患者的 10 只眼接受了 TCZ 治疗。患者的中位年龄为 14 岁（范围为 7-24 岁）。TCZ 治疗的中位时间为 15 个月（范围为 5-32 个月）。CST 从 373±101.0μm 平均降低至 298.2±40.3μm。FA 评分从 12.5±4.3 平均降低至 3.6±2.6。1 例患者出现肝转氨酶升高。
结论
IV TCZ 是治疗难治性非感染性葡萄膜炎的一种潜在有效且安全的治疗选择。
Zotero 插件